Learn About an HES Treatment Option | NUCALA (mepolizumab) for
NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non


















